Sofinnova Partners

Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs and occasionally restarts. Our focus is on life sciences. We proactively source deals, take a lead role, we are most often the first institutional investor in Round A financings, and we lead our portfolio companies until exit. We sit on the boards of our portfolio companies and play an active role as from the formation phase alongside our entrepreneurs. Sofinnova invests throughout Europe from our headquarters in Paris with a portion of our investments made in the rest of the world.

TypeInvestor
HQParis, FR
Founded1972
Websitesofinnova.fr
Cybersecurity ratingAMore
Sofinnova Partners was founded in 1972 and is headquartered in Paris, FR

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Sofinnova Partners

Rafaèle Tordjman

Rafaèle Tordjman

Managing Partner
Denis Lucquin

Denis Lucquin

Managing Partner
Graziano Seghezzi

Graziano Seghezzi

Managing Partner, Partner
Antoine Papiernik

Antoine Papiernik

Chairman
Monique Saulnier

Monique Saulnier

Managing Partner & CFO
Henrijette Richter

Henrijette Richter

Partner
Show more

Sofinnova Partners Office Locations

Sofinnova Partners has an office in Paris
Paris, FR (HQ)
7 Boulevard Haussmann
Show all (1)

Sofinnova Partners Investment Portfolio

Stage Distribution

20022021

Top Sectors Distribution

20022021

Round Size Distribution

20022021

Sofinnova Partners News and Updates

Sofinnova Partners closes crossover fund at €445 Million

Paris, London and Milan-based Sofinnova Partners has recently announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million. This now comprises the largest crossover investor dedicated late-stage biopharma and medtech fund in Europe. Sofinnova is expected to Main…

Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners

BASEL, Switzerland, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announced it has successfully concluded an oversubscribed Series A financing round, raising CHF54 million ($59 million USD) to fund further…

Sofinnova Partners leads Series A round for DMC

DMC, an early-stage biotech company, has secured an undisclosed amount of Series A funding. Sofinnova Partners led the round.

Sofinnova Partners recruits Bhaman as partner

Sofinnova Partners, a European life sciences venture firm, has appointed Maina Bhaman as a partner. Previously, she worked at Touchstone Innovations where she was director of healthcare investment.

Sofinnova Partners appoints Seghezzi as managing partner

Sofinnova Partners has named Graziano Seghezzi as a managing partner. Seghezzi first joined the venture firm in 2001.

Sofinnova Partners Online and Social Media Presence

Embed Graph

Sofinnova Partners Blogs

TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage

Paris, France, August 31, 2021 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to…

Sofinnova Partners Closes €63M ($75M) Oversubscribed Medtech Acceleration Fund

Capital raise enables Sofinnova MD Start’s pioneering team to further support clinicians in transforming innovative ideas into medical realities Paris – July 13, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today th…

Biotalys announces successful €54.6 million Initial Public Offering

Ghent, BELGIUM – 01 July 2021 – Biotalys NV (“Biotalys” or the “Company”) an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces the results of its initial p…

Sofinnova Partners announces three new investments from its fund dedicated to Italian scientific research

Key investments made through the Sofinnova Telethon Fund underscore the venture capital firm’s commitment to fostering a thriving Italian biotech ecosystem AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics are developing promising new therapies for rare, genetic disordersMilan, Italy …

Medtech Accelerator Sofinnova MD Start III Launches a Call for early stage Medical Device Projects

PARIS, France – June 8, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofi…

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

PARIS, France, May 24, 2021 – 6:30 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces positive phase 2b clini…
Show more

Sofinnova Partners Frequently Asked Questions

  • When was Sofinnova Partners founded?

    Sofinnova Partners was founded in 1972.

  • Who are Sofinnova Partners key executives?

    Sofinnova Partners's key executives are Rafaèle Tordjman, Denis Lucquin and Graziano Seghezzi.

  • Where is Sofinnova Partners headquarters?

    Sofinnova Partners headquarters is located at 7 Boulevard Haussmann, Paris.

  • Where are Sofinnova Partners offices?

    Sofinnova Partners has an office in Paris.

  • How many offices does Sofinnova Partners have?

    Sofinnova Partners has 1 office.